In anemia, insufficient numbers of circulating red blood cells or inadequate quantities of iron or functional hemoglobin (Hb) are available to transport and release oxygen to tissues. Anemia is common in patients with chronic kidney disease (CKD).

ICER will assess the comparative clinical effectiveness and value of roxadustat (FibroGen, Inc.) for treatment of anemia in chronic kidney disease (CKD). Roxadustat is currently undergoing FDA review, with an anticipated decision expected at the end of this year.

Interventions of Interest:

  • roxadustat (FibroGen, Inc.)

Date of Review: February 2021

For questions or additional information, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer.org.

View the Key Stakeholders List.